Phase II trial (Investigator-initiated clinical trial) of CH5424802 in patients with relapsed or refractory ALK-positive anaplastic large cell lymphoma
Active, no longer recruiting
Phase of Trial: Phase II
Latest Information Update: 04 Oct 2017
At a glance
- Drugs Alectinib (Primary)
- Indications Anaplastic large cell lymphoma
- Focus Therapeutic Use
- 02 Oct 2017 Planned End Date changed from 31 Mar 2017 to 31 Mar 2020.
- 25 Jul 2017 Status changed from recruiting to active, no longer recruiting.
- 22 Apr 2016 Planned End Date changed from 31 Dec 2017 to 21 Feb 2016.